ECSP19086712A - Compuestos y composiciones para inducir la condrogénesis - Google Patents
Compuestos y composiciones para inducir la condrogénesisInfo
- Publication number
- ECSP19086712A ECSP19086712A ECSENADI201986712A ECDI201986712A ECSP19086712A EC SP19086712 A ECSP19086712 A EC SP19086712A EC SENADI201986712 A ECSENADI201986712 A EC SENADI201986712A EC DI201986712 A ECDI201986712 A EC DI201986712A EC SP19086712 A ECSP19086712 A EC SP19086712A
- Authority
- EC
- Ecuador
- Prior art keywords
- compounds
- induce
- compositions
- present
- pharmaceutically acceptable
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 230000022159 cartilage development Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 230000006378 damage Effects 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 1
- 208000027418 Wounds and injury Diseases 0.000 abstract 1
- 210000001612 chondrocyte Anatomy 0.000 abstract 1
- 230000002648 chondrogenic effect Effects 0.000 abstract 1
- 230000004069 differentiation Effects 0.000 abstract 1
- 210000003035 hyaline cartilage Anatomy 0.000 abstract 1
- 208000014674 injury Diseases 0.000 abstract 1
- 210000001503 joint Anatomy 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 210000000130 stem cell Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0655—Chondrocytes; Cartilage
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/999—Small molecules not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/14—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from hepatocytes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762517394P | 2017-06-09 | 2017-06-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP19086712A true ECSP19086712A (es) | 2019-12-27 |
Family
ID=62837959
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSENADI201986712A ECSP19086712A (es) | 2017-06-09 | 2019-12-05 | Compuestos y composiciones para inducir la condrogénesis |
Country Status (38)
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY37759A (es) | 2017-06-09 | 2019-01-31 | Novartis Ag | Compuestos y composiciones para inducir condrogénesis |
| CN113015735B (zh) * | 2018-12-06 | 2024-06-21 | 诺华股份有限公司 | 用于诱导软骨发生以治疗关节损害的5-羟基-7-氧杂双环[2.2.1]庚烷-2-甲酰胺衍生物 |
| ES2965684T3 (es) | 2018-12-06 | 2024-04-16 | Novartis Ag | Derivados de 6-hidroxi-8-oxatriciclo[3.2.1.02,4]octano-2-carboxamida para inducir condrogénesis para el tratamiento del daño articular |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998030566A1 (en) * | 1997-01-06 | 1998-07-16 | Pfizer Inc. | Cyclic sulfone derivatives |
| ECSP982358A (es) | 1998-01-06 | 1998-12-22 | Derivados ciclicos de sulfona | |
| US6407250B1 (en) * | 2000-09-14 | 2002-06-18 | Allergan Sales, Inc. | Interphenylene 7-oxabicyclic [2.2.1] heptane oxazoles as prostaglandin F2a antagonists |
| US6369089B1 (en) | 2000-09-14 | 2002-04-09 | Allergan Sales, Inc. | Interheteroaryl 7-oxabicyclic [2.2.1]heptane oxazoles as prostaglandin F2α antagonists |
| CN1213050C (zh) | 2000-11-23 | 2005-08-03 | 拜尔公司 | 氧杂双环[2.2.1]庚烷衍生物，其制备方法和作为农药的用途 |
| US6653468B1 (en) | 2002-07-31 | 2003-11-25 | Isis Pharmaceuticals, Inc. | Universal support media for synthesis of oligomeric compounds |
| JP2005068052A (ja) | 2003-08-22 | 2005-03-17 | Mitsui Chemicals Inc | 新規なフラン誘導体及びその製造方法 |
| WO2006038112A1 (en) | 2004-10-01 | 2006-04-13 | Warner-Lambert Company Llc | Use of kinase inhibitors to promote neochondrogenesis |
| US7595327B2 (en) * | 2005-03-21 | 2009-09-29 | Wyeth | Beta-sulfonamide hydroxamic acid inhibitors of tace/matrix metalloproteinase |
| WO2008008884A2 (en) | 2006-07-12 | 2008-01-17 | Cornell Research Foundation, Inc. | Inhibition of beta-amyloid peptide aggregation |
| JO3240B1 (ar) | 2007-10-17 | 2018-03-08 | Janssen Pharmaceutica Nv | c-fms مثبطات كيناز |
| US20100256385A1 (en) | 2009-04-02 | 2010-10-07 | Allergan, Inc. | Prostaglandin e receptor antagonists |
| AU2010273570B2 (en) | 2009-07-14 | 2014-07-03 | Novartis Ag | Mesenchymal stem cell differentiation |
| CN101628951B (zh) | 2009-08-12 | 2011-06-22 | 中国石油天然气股份有限公司 | 烯烃聚合用固体催化组分及其催化剂 |
| EP2651405A2 (en) | 2010-12-14 | 2013-10-23 | Electrophoretics Limited | Casein kinase 1 (ck1 ) inhibitors |
| WO2012129562A2 (en) | 2011-03-24 | 2012-09-27 | The Scripps Research Institute | Compounds and methods for inducing chondrogenesis |
| WO2012177856A2 (en) | 2011-06-21 | 2012-12-27 | Adispell, Inc. | Cognition modification |
| WO2013007765A1 (en) * | 2011-07-13 | 2013-01-17 | F. Hoffmann-La Roche Ag | Fused tricyclic compounds for use as inhibitors of janus kinases |
| ES2900815T3 (es) | 2013-03-15 | 2022-03-18 | Scripps Research Inst | Compuestos y métodos para inducir la condrogénesis |
| EP3143026B1 (en) * | 2014-05-13 | 2024-07-10 | Novartis AG | Compounds and compositions for inducing chondrogenesis |
| JP2016204316A (ja) | 2015-04-24 | 2016-12-08 | 日東電工株式会社 | 核酸固相合成用リンカー及び担体 |
| UY37759A (es) | 2017-06-09 | 2019-01-31 | Novartis Ag | Compuestos y composiciones para inducir condrogénesis |
-
2018
- 2018-06-05 UY UY0001037759A patent/UY37759A/es active IP Right Grant
- 2018-06-06 AR ARP180101514A patent/AR113227A1/es unknown
- 2018-06-07 IL IL300755A patent/IL300755A/en unknown
- 2018-06-07 HU HUE21178695A patent/HUE065194T2/hu unknown
- 2018-06-07 LT LTEP21178695.9T patent/LT3915994T/lt unknown
- 2018-06-07 PE PE2019002520A patent/PE20200403A1/es unknown
- 2018-06-07 MA MA57022A patent/MA57022B1/fr unknown
- 2018-06-07 SI SI201831061T patent/SI3915994T1/sl unknown
- 2018-06-07 MA MA050547A patent/MA50547A/fr unknown
- 2018-06-07 BR BR112019025866-3A patent/BR112019025866A2/pt not_active Application Discontinuation
- 2018-06-07 JO JOJO/P/2019/0282A patent/JOP20190282B1/ar active
- 2018-06-07 AU AU2018279306A patent/AU2018279306C1/en active Active
- 2018-06-07 HR HRP20240155TT patent/HRP20240155T1/hr unknown
- 2018-06-07 WO PCT/IB2018/054123 patent/WO2018225009A1/en not_active Ceased
- 2018-06-07 EP EP23203447.0A patent/EP4299123A3/en active Pending
- 2018-06-07 CN CN201880037287.1A patent/CN110719913B/zh active Active
- 2018-06-07 EA EA201992858A patent/EA201992858A1/ru unknown
- 2018-06-07 EP EP21178695.9A patent/EP3915994B9/en active Active
- 2018-06-07 CA CA3063985A patent/CA3063985A1/en active Pending
- 2018-06-07 US US16/620,407 patent/US11091499B2/en active Active
- 2018-06-07 CR CR20190551A patent/CR20190551A/es unknown
- 2018-06-07 KR KR1020207000290A patent/KR102656524B1/ko active Active
- 2018-06-07 CU CU2019000098A patent/CU24577B1/es unknown
- 2018-06-07 MY MYPI2019006646A patent/MY198288A/en unknown
- 2018-06-07 FI FIEP21178695.9T patent/FI3915994T3/fi active
- 2018-06-07 DK DK21178695.9T patent/DK3915994T3/da active
- 2018-06-07 RS RS20240179A patent/RS65161B1/sr unknown
- 2018-06-07 TW TW107119618A patent/TWI782036B/zh active
- 2018-06-07 EP EP18737718.9A patent/EP3634967A1/en not_active Withdrawn
- 2018-06-07 PL PL21178695.9T patent/PL3915994T3/pl unknown
- 2018-06-07 MX MX2019014757A patent/MX389169B/es unknown
- 2018-06-07 ES ES21178695T patent/ES2971319T3/es active Active
- 2018-06-07 PT PT211786959T patent/PT3915994T/pt unknown
- 2018-06-07 JP JP2019567650A patent/JP7229945B2/ja active Active
-
2019
- 2019-11-06 ZA ZA2019/07358A patent/ZA201907358B/en unknown
- 2019-12-03 IL IL271154A patent/IL271154B2/en unknown
- 2019-12-05 CO CONC2019/0013706A patent/CO2019013706A2/es unknown
- 2019-12-05 SA SA519410729A patent/SA519410729B1/ar unknown
- 2019-12-05 EC ECSENADI201986712A patent/ECSP19086712A/es unknown
- 2019-12-05 CL CL2019003564A patent/CL2019003564A1/es unknown
- 2019-12-05 DO DO2019000305A patent/DOP2019000305A/es unknown
- 2019-12-06 PH PH12019502764A patent/PH12019502764A1/en unknown
-
2021
- 2021-07-06 US US17/368,537 patent/US11753416B2/en active Active
-
2023
- 2023-02-15 JP JP2023021335A patent/JP7432778B2/ja active Active
- 2023-07-18 US US18/354,163 patent/US12209096B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY36118A (es) | Compuestos y composiciones para inducir condrogénesis | |
| MX2019010541A (es) | Compuestos de imidazo-piperidina fusionada como inhibidores de jak. | |
| MX2020012520A (es) | Macrociclos con grupos p2' heterociclicos como inhibidores del factor xia. | |
| CU20140072A7 (es) | Derivados de dihidro-oxazina y dihidro-pirido-oxazina | |
| CO6460766A2 (es) | Compuestos de haloalquil heteroaril benzamida | |
| CR20200484A (es) | COMPUESTOS DE DIHIDROISOQUINOLINONA SUSTITUIDA (Divisional 2016-0574) | |
| MX2012004311A (es) | Derivados de ciclohexano spiro condensados como inhibidores de lipasa sensible a hormonas (hsl) utiles en el tratamiento de diabetes. | |
| ECSP12012103A (es) | Inhibidores de virus flaviviridae. | |
| CO6612267A2 (es) | Nuevos derivados de 1,1 dióxido- 5 fenil- 2,3,4-5tetrahidro- 1,4-benzotiazepina y composiciones farmaceúticas que los comprenden | |
| PE20170303A1 (es) | Derivados de la indolizina como inhibidores de las fosfoinositido-3 quinasas | |
| MX343160B (es) | Dicetopiperazinas para uso en inhibir hiperpermeabilidad vascular. | |
| ECSP14013157A (es) | Formulaciones liofilizadas de fgf-18 | |
| BR112014010407A2 (pt) | compostos de azetidina, composições e seu uso como inibidores de hidrolase de epóxido solúvel | |
| DOP2019000305A (es) | Compuestos y composiciones para inducir la condrogénesis | |
| CR20150419A (es) | Derivados sustituidos del ácido bisfenil butanóico fosfónico como inhibidores de la nep | |
| UY35419A (es) | Inhibidores de cdk9 quinasa de pirrolo (2,3- b) piridina | |
| PY1515461A (es) | Derivados de Dihidropirrolopirimidina | |
| AR102562A1 (es) | Métodos para tratar la enfermedad de huntington usando composiciones de cisteamina | |
| ECSP17003149A (es) | Compuestos de dihidroisoquinolinona sustituida | |
| CU20140033A7 (es) | Derivados de pirrolopirimidina y purina | |
| PA8768201A1 (es) | Composiciones farmacéuticas que contienen derivados de ácido indol sustituidos como inhibidores del inhibidor del activador de plasminógeno 1 (pai-1) | |
| ECSP11010817A (es) | Agentes antifúngicos |